TBP

DGAP-News: Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF(TM)

Thursday, October 14, 2021 - 2:29pm

Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.

Key Points: 
  • Since the beginning of the clinical development program in late-2016, QIXLEEF(TM) strictly adhered to and complied with the regulatory requirements of a prescription drug.
  • Having a global drug development strategy ensures economy of scale and lower cost of drug development to shareholders.
  • The REBORN(c) clinical strategy provides the fastest and lowest cost development program to bring QIXLEEF(TM) to the market.
  • Guy Chamberland, CEO and CRO commented, "Our team has made significant progress in bringing QIXLEEF(TM) to a late clinical development stage.

Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™

Thursday, October 14, 2021 - 11:30am

Since the beginning of the clinical development program in late-2016, QIXLEEF strictly adhered to and complied with the regulatory requirements of a prescription drug.

Key Points: 
  • Since the beginning of the clinical development program in late-2016, QIXLEEF strictly adhered to and complied with the regulatory requirements of a prescription drug.
  • The Company completed two Phase 1 clinical trials in healthy volunteers to assess the safety profile, including cardiovascular, pharmacodynamics and pharmacokinetics, of smoked and vaporized QIXLEEF.
  • The REBORN clinical strategy provides the fastest and lowest cost development program to bring QIXLEEF to the market.
  • Guy Chamberland, CEO and CRO commented, "Our team has made significant progress in bringing QIXLEEF to a late clinical development stage.

REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.

Tuesday, October 5, 2021 - 12:30pm

We remain confident that REDUVO shall receive a Notice of Compliance (NoC) from Health Canada in the coming months.

Key Points: 
  • We remain confident that REDUVO shall receive a Notice of Compliance (NoC) from Health Canada in the coming months.
  • REDUVO willhelp us create ourCanadianfootprint with healthcare professionalstoestablishour leading position in cannabinoid-derived medicines."
  • REDUVO will pave the way for the global drug launch of REDUVO Adversa in 2024, a dronabinol administered product through an innovative mucoadhesive tablet delivery system, including patent protection.
  • REDUVO Adversa cumulative global gross sales are expected to reach $79M by 2026.

CEMATRIX Announces the retirement of Dan Koyich and the appointment of John Kim to the Board of Directors

Friday, October 1, 2021 - 1:25pm

Mr. Dan Koyich has retired from the Board of Directors effective September 30th, 2021.

Key Points: 
  • Mr. Dan Koyich has retired from the Board of Directors effective September 30th, 2021.
  • Dan has provided strategic leadership since the early days of CEMATRIX and has continued to provide valuable counsel to the board and our staff, said Minaz Lalani, Chairman of the Board of Directors.
  • CEMATRIX is also pleased to announce the appointment of Mr. John Kim to the Company's Board of Directors (the "Board").
  • "We are very excited to welcome John to CEMATRIXs Board," said Jeff Kendrick, CEO of CEMATRIX.

Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™

Thursday, September 2, 2021 - 11:30am

OTTAWA, ON, Sept. 2, 2021 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the"Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority.

Key Points: 
  • OTTAWA, ON, Sept. 2, 2021 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the"Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it received the Scientific Advice Assessment (SAA) Report from the Malta Medicines Authority.
  • Overall, the SAA Report provided positive feedback on Tetra's drug development plan for QIXLEEFand eligibility for submitting a Marketing Authorization Application (MAA) under Directive 2001/83/EC (Directive).
  • The SAA Report endorses Tetra's proposed plan to address the nonclinical safety requirements for submitting a MAA for QIXLEEF.
  • The SAA Report discusses the assessment of both the PLENITUDE and REBORN clinical programs with regards to a MAA.

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Thursday, July 29, 2021 - 12:30pm

OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Key Points: 
  • OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.
  • GRAS status will allow for the broad application of this novel ingredient in foods as well as dietary supplements.
  • Research conducted through Tetra has shown that cannabis plant residue can increase the growth of beneficial gut microbes including bothLactobaccillus rhamnosusandBifidobacterium longum.
  • If granted, this patent application will provide Tetra with protection for the use of cannabis plant residue material containing residual cannabinoids within a specified profile range, as an oral prebiotic component alone or in combination with other pro, post, para, or prebiotics as a dietary supplement for gastrointestinal health.